Nisha Marathe

Director/Board Member at Soteria Biotherapeutics, Inc.

Finance

Health Technology

Profile

Nisha Marathe has worked as an Investment Director at Roche Ventures since 2020.
She is also currently a Director at Soteria Biotherapeutics, Inc.

Nisha Marathe active positions

Companies	Position	Start
Roche Ventures Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.	Private Equity Investor	31/12/2017
Soteria Biotherapeutics, Inc. Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA.	Director/Board Member	-

All active positions of Nisha Marathe

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nisha Marathe's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Roche Ventures Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.	Finance
Soteria Biotherapeutics, Inc. Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA.	Health Technology